Top Big Cap Negative News Movers Premarket: ADBE: -4% Earnings SMR: -3.5% Downgraded to SELL @ UBS EXEL: -3% FDA Extended Review Period for
Top Big Cap Negative News Movers Premarket: ADBE: -4% Earnings SMR: -3.5% Downgraded to SELL @ UBS EXEL: -3% FDA Extended Review Period for Colorectal Cancer Drug
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.